IMM 0.00% 34.0¢ immutep limited

Ann: Immutep presents positive TACTI-mel melanoma trial data, page-2

  1. 1,426 Posts.
    lightbulb Created with Sketch. 73
    • Favourable safety profile of eftilagimod alpha in combination with pembrolizumab
    • Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively
    • Disease Control Rate of 66% of patients in each Part A and B (24 patients in total)
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
0.000(0.00%)
Mkt cap ! $493.8M
Open High Low Value Volume
34.5¢ 35.0¢ 33.5¢ $724.1K 2.106M

Buyers (Bids)

No. Vol. Price($)
3 60483 34.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.5¢ 55452 4
View Market Depth
Last trade - 16.10pm 29/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.